Velinotamig (GR1803) vs YKST02

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Multiple Myeloma

Shared mechanism: BCMA x CD3 · full Multiple Myeloma pipeline

Velinotamig (GR1803)

Developed by Cullinan Therapeutics Inc. under a licence from Genrix Bio

Phase 3 in Multiple Myelomabiologic (bispecific antibody, BCMA x CD3 T-cell engager)
Weak signal

NCT07102706 · Phase 1/2 · completed

The study assigned participants sequentially to different GR1803 doses without randomization, blinding, or a control group. Its primary endpoint was dose-limiting toxicity over 52 weeks, but the registry does not report whether this endpoint was met.

Next expected readout: May 2027 · NCT06566547 (registry estimate)

No aligned efficacy figure on record for this race.

YKST02

Developed by EXCYTE (Beijing) Pharmaceutical Technology Development Co., Ltd.

Phase 2 in Multiple Myelomabispecific antibody
not yet graded

No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.

Next expected readout: December 2026 · NCT06574568 (registry estimate)

No aligned efficacy figure on record for this race.

Results for Multiple Myeloma

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointVelinotamig (GR1803)YKST02
PFS, median—Trial running · NCT07452198—Not reported
OS, median—Trial running · NCT07452198—Not reported
ORR—Trial running · NCT07452198—Not reported
VGPR or better—Trial running · NCT07452198—Not reported
MRD negativity—Trial running · NCT07452198—Not reported

PFS, median

Velinotamig (GR1803)
—Trial running · NCT07452198
YKST02
—Not reported

OS, median

Velinotamig (GR1803)
—Trial running · NCT07452198
YKST02
—Not reported

ORR

Velinotamig (GR1803)
—Trial running · NCT07452198
YKST02
—Not reported

VGPR or better

Velinotamig (GR1803)
—Trial running · NCT07452198
YKST02
—Not reported

MRD negativity

Velinotamig (GR1803)
—Trial running · NCT07452198
YKST02
—Not reported
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.

Velinotamig (GR1803): no structured comparison results are available for Multiple Myeloma.

YKST02: no structured comparison results are available for Multiple Myeloma.

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Velinotamig (GR1803)'s landscape · YKST02's landscape